Detailed explanation of the difference between durvalumab (durvalumab) and whether it is a targeted drug or an immunotherapy drug

Durvalumab (durvalumab) is an immunotherapy drug, specifically an immune checkpoint inhibitor. It blocks the combination of the programmed death ligand 1 (PD-L1) on the surface of tumor cells and the programmed death receptor 1 (PD-1) on immune cells, thereby lifting the tumor's suppression of the immune system, thereby activating the patient's own immune system to attack cancer cells. This mechanism allows durvalumab to show significant efficacy in the treatment of various malignant tumors.

Targeted drugs are usually drugs that target specific genes, proteins or signaling pathways within tumor cells or on the cell surface. They inhibit the proliferation and spread of cancer cells by directly acting on specific targets of cancer cells and blocking tumor growth signals. In contrast, immunotherapy drugs such as durvalumab do not directly act on the tumor cells themselves, but modulate the patient's immune system so that immune cells can recognize and kill cancer cells.

Dervalumab is mainly used to treat various tumors such as non-small cell lung cancer and urothelial cancer. It is an important breakthrough in the field of immunotherapy in recent years. Its use is usually based on the patient's tumor PD-L1 expression level and specific clinical protocols, and the therapeutic effect is different from traditional targeted drugs. Immunotherapy can sometimes bring the possibility of long-term relief or even cure, but it also has immune-related side effects and needs to be used rationally under the guidance of a professional doctor.

In general, durvalumab is an immunotherapy drug rather than a targeted drug in the traditional sense. It exerts anti-cancer effects by activating the human immune system, while targeted drugs directly inhibit the growth of cancer cells by precisely blocking specific tumor targets. Understanding the difference between the two can help patients and doctors choose and match treatment plans rationally and improve treatment effects.

Reference materials:https://www.imfinzi.com/